{"schema_version":"secwatch.filing_event.v1","accession":"0001439222-25-000076","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2025-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.000258+00:00","generated_at":"2026-05-18T09:04:11.216028+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Agios Pharmaceuticals elects Jay Backstrom, M.D., MPH to board","bullets":["Dr. Backstrom appointed as Class III director, term until 2028 Annual Meeting.","Appointed to Science and Technology Committee of the Board effective July 8, 2025.","Initial compensation includes stock option with $472,500 Black-Scholes value and RSUs valued at $157,500.","Annual cash compensation: $50,000 for board service plus $7,500 for committee service, quarterly pro-rata."],"urls":{"canonical":"https://secwatch.observer/filing/0001439222-25-000076","json":"https://secwatch.observer/filing/0001439222-25-000076.json","markdown":"https://secwatch.observer/filing/0001439222-25-000076.md","text":"https://secwatch.observer/filing/0001439222-25-000076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000076/0001439222-25-000076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000076/agio-20250703.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:04:11.216028+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}